YM-53601

YM-53601, a squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in vivo[1]. YM-53601 inhibits squalene synthase derived from human hepatoma cells with an IC50 of 79 nM. Lipid-lowering agent[2]. YM-53601 is also an inhibitor of farnesyl-diphosphate farnesyltransferase 1 (FDFT1) enzyme activity and abrogates HCV propagation[3].

Product Specifications

CAS Number

[182959-33-7]

UNSPSC

12352005

Hazard Statement

H302, H315, H319

Target

Farnesyl Transferase; HCV

Type

Reference compound

Related Pathways

Anti-infection; Metabolic Enzyme/Protease

Applications

Metabolism-sugar/lipid metabolism

Field of Research

Infection; Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/ym-53601.html

Purity

99.37

Solubility

DMSO : 100 mg/mL (ultrasonic; warming; heat to 60°C)

Smiles

F/C(COC1=CC(NC2=C3C=CC=C2)=C3C=C1)=C4CN5CCC/4CC5.[H]Cl

Molecular Formula

C21H22ClFN2O

Molecular Weight

372.86

Precautions

H302, H315, H319

References & Citations

[1]T Ugawa, et al. YM-53601, a novel squalene synthase inhibitor, reduces plasma cholesterol and triglyceride levels in several animal species. Br J Pharmacol. 2000 Sep;131 (1) :63-70. |[2]Tsukasa Ishihara, et al. Syntheses of 3-ethylidenequinuclidine derivatives as squalene synthase inhibitors. Part 2: enzyme inhibition and effects on plasma lipid levels. Bioorg Med Chem. 2003 Aug 15;11 (17) :3735-45. |[3]Eun-Mee Park, et al. Farnesyl-diphosphate farnesyltransferase 1 regulates hepatitis C virus propagation. FEBS Lett. 2014 May 2;588 (9) :1813-20. |[4]Joan Montero, et al.Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular carcinoma. Cancer Res. 2008 Jul 1;68 (13) :5246-56.